Acrux Ltd 2022 Annual Report with Sustainability Disclosures
Company: Acrux Ltd
Sector: Manufacturing
Country: Australia
Year: 2022
Type: Annual Report with Sustainability Disclosures
Pages: 68
The report describes continued FY22 product-pipeline progress, including FDA approval for Lidocaine 2.5% and Prilocaine 2.5% Cream and the launch of Testosterone Topical Solution. Group revenue was $5.103 million, while the consolidated net loss was $9.834 million. The ESG section organizes the company's responsible-business approach around environmental, social and governance tenets covering environmental impact, patient and employee safety, and corporate governance.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.